Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus DETROL LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus DETROL LA.
CANTIL vs DETROL LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Category C
Category C
Anticholinergic / Antispasmodic
Anticholinergic